PMID- 26966633 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160311 LR - 20200929 IS - 2155-1790 (Print) IS - 2155-1790 (Electronic) IS - 2155-1790 (Linking) VI - 1 IP - 2 DP - 2010 TI - In Vivo Growing of New Cell Colonies in a Portion of Bone Marrow: Potential Use for Indirect Cell Therapy. PG - 93-103 LID - 10.3727/215517910X528969 [doi] AB - The ability of bone marrow cells (BMCs) to migrate to different organs can be used for indirect cell therapy, a procedure based on the engraftment of therapeutic cells in a different place from where they will finally move to and perform their action and which could be particularly useful for chronic illness where a persistent and long-lasting therapeutic action is required. Thus, establishing a stable colony of engineered BMCs is a requisite for the chronic provision of damaged tissues with engineered cells. Reported here is a procedure for creating such a cell colony in a portion of the bone marrow (BM). The study was performed in C57BL/6j mice and consisted of developing a focal niche in a portion of the bone marrow with focal irradiation so that it could be selectively colonized by BM cells (C57BL/6-FG-VC-GFP mice) injected in the blood stream. Both the arrival of cells coming from the nonirradiated BM (week 1 after irradiation) and the proliferation of cells in the irradiated BM (week 2) prevented the homing of injected cells in the BM niche. However, when BMCs were injected in a time window about 48 h after irradiation they migrated to the BM niche where they established a cell colony able to: 1) survive for a long period of time [the percentage of injected cells increased in the BM from day 30 postinjection (15%) to day 110 postinjection 28%)]; 2) express cell differentiation markers (90% of them were lineage committed 4 weeks after engraftment); and 3) colonize to the blood stream (with 5% and 9% of all blood cells being computed 1 and 3 months after engraftment, respectively). The intravenous injection of BMCs in combination with a previous transitory focal myeloablation is a safe and easy method for creating the long-lasting colony of modified BMCs needed for treating chronic and progressive illness with indirect cell therapy. FAU - Manzanedo, Ana AU - Manzanedo A AD - Laboratory of Neurobiology and Experimental Neurology, Department of Physiology, Faculty of Medicine, University of La Laguna , La Laguna, Tenerife, Canary Islands , Spain. FAU - Rodriguez, Fidel AU - Rodriguez F AD - dagger Department of Pharmacology and Physical Medicine, Faculty of Medicine, University of La Laguna , La Laguna, Tenerife, Canary Islands , Spain. FAU - Obeso, Jose A AU - Obeso JA AD - double daggerDepartment of Neurology and Neurosurgery, Clinica Universitaria and Medical School, Centro de Investigacion Medica Aplicada (CIMA), University of Navarra, Pamplona, Spain; section signCentro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. FAU - Rodriguez, Manuel AU - Rodriguez M AD - Laboratory of Neurobiology and Experimental Neurology, Department of Physiology, Faculty of Medicine, University of La Laguna, La Laguna, Tenerife, Canary Islands, Spain; section signCentro de Investigacion Biomedica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain. LA - eng PT - Journal Article DEP - 20101105 PL - United States TA - Cell Med JT - Cell medicine JID - 101544564 PMC - PMC4776168 OTO - NOTNLM OT - Bone marrow OT - Cell transplantation OT - GFP OT - Myeloablation OT - Parkinson's disease OT - Stem cells EDAT- 2010/01/01 00:00 MHDA- 2010/01/01 00:01 PMCR- 2010/11/05 CRDT- 2016/03/12 06:00 PHST- 2016/03/12 06:00 [entrez] PHST- 2010/01/01 00:00 [pubmed] PHST- 2010/01/01 00:01 [medline] PHST- 2010/11/05 00:00 [pmc-release] AID - CM-1-093 [pii] AID - 10.3727/215517910X528969 [doi] PST - epublish SO - Cell Med. 2010 Nov 5;1(2):93-103. doi: 10.3727/215517910X528969. eCollection 2010.